$BIXT
BIOXYTRAN, INC Stock $bixt

$bixt Overview Financials Valuation SEC Filings Company Website

2024 Q3 Form 10-Q Financial Statement

#000149315224032356 Filed on August 14, 2024

Income Statement

Concept	2024 Q3	2024 Q2
Revenue		$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin		$609.4K
YoY Change		-30.12%
% of Gross Profit
Research & Development	$51.00K
YoY Change	-83.87%
% of Gross Profit
Depreciation & Amortization		$1.540K
YoY Change		-29.68%
% of Gross Profit
Operating Expenses	$346.2K	$609.4K
YoY Change	-64.87%	-40.35%
Operating Profit	-$346.2K	-$609.4K
YoY Change	-64.87%	-40.35%
Interest Expense		-$50.79K
YoY Change		-86.91%
% of Operating Profit
Other Income/Expense, Net	-$46.17K	-$52.33K
YoY Change	-8.58%	-86.59%
Pretax Income	-$392.4K	-$661.7K
YoY Change	-62.12%	-53.14%
Income Tax
% Of Pretax Income
Net Earnings	-$392.4K	-$661.7K
YoY Change	-60.81%	-53.11%
Net Earnings / Revenue
Basic Earnings Per Share	$0.00	$0.00
Diluted Earnings Per Share	$0.00	$0.00
COMMON SHARES
Basic Shares Outstanding	178.0M shares	175.0M shares
Diluted Shares Outstanding	126.4M shares	176.6M shares

Balance Sheet

Concept	2024 Q3	2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments		$13.52K
YoY Change		-70.08%
Cash & Equivalents	$34.67K	$13.52K
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$34.67K	$13.52K
YoY Change	-56.81%	-70.07%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$124.3K	$115.0K
YoY Change	14.31%	17.52%
TOTAL ASSETS
Total Short-Term Assets	$34.67K	$13.52K
Total Long-Term Assets	$124.3K	$115.0K
Total Assets	$159.0K	$128.6K
YoY Change	-15.89%	-10.14%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable		$324.3K
YoY Change		61.75%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt		$768.0K
YoY Change		-61.6%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$1.244M	$1.229M
YoY Change	-46.7%	-55.64%
LONG-TERM LIABILITIES
Long-Term Debt		$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities		$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.244M	$1.229M
Total Long-Term Liabilities		$0.00
Total Liabilities	$1.244M	$1.229M
YoY Change	-46.7%	-55.64%
SHAREHOLDERS EQUITY
Retained Earnings	-$18.30M	-$16.96M
YoY Change	26.63%	26.43%
Common Stock	$17.19M	$177.4K
YoY Change	11804.95%	34.37%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity		-$405.8K
YoY Change
Total Liabilities & Shareholders Equity	$159.0K	$128.6K
YoY Change	-15.89%	-10.14%

Cashflow Statement

Concept	2024 Q3	2024 Q2
OPERATING ACTIVITIES
Net Income	-$392.4K	-$661.7K
YoY Change	-60.81%	-53.11%
Depreciation, Depletion And Amortization		$1.540K
YoY Change		-29.68%
Cash From Operating Activities		-$54.45K
YoY Change		-64.48%
INVESTING ACTIVITIES
Capital Expenditures		$1.050K
YoY Change		-94.84%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities		-$1.050K
YoY Change		-94.84%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		59.00K
YoY Change		-9.23%
NET CHANGE
Cash From Operating Activities		-54.45K
Cash From Investing Activities		-1.050K
Cash From Financing Activities		59.00K
Net Change In Cash		3.500K
YoY Change		-103.22%
FREE CASH FLOW
Cash From Operating Activities		-$54.45K
Capital Expenditures		$1.050K
Free Cash Flow		-$55.50K
YoY Change		-68.03%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q2	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2024Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2024Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
CY2024Q2	us-gaap	Share Based Compensation ShareBasedCompensation	10691	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	111552	usd
CY2023Q4	us-gaap	Assets Assets	137638	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	296312	usd
CY2023Q2	BIXT	General And Administrative Affiliate GeneralAndAdministrativeAffiliate	298000	usd
	BIXT	General And Administrative Affiliate GeneralAndAdministrativeAffiliate	391844	usd
CY2024Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense		usd
CY2023Q2	BIXT	Interest Expense Affiliate InterestExpenseAffiliate		usd
	BIXT	Interest Expense Affiliate InterestExpenseAffiliate		usd
CY2024Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2024Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest		usd
CY2024Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues		usd
CY2024Q1	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther		usd
CY2024Q1	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits		usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt		usd
	us-gaap	Interest Paid Net InterestPaidNet		usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
	BIXT	Non Cash Issuance Of Warrants NonCashIssuanceOfWarrants		usd
	BIXT	Debt Discount On Convertible Note DebtDiscountOnConvertibleNote		usd
	us-gaap	Stock Issued1 StockIssued1		usd
	BIXT	Common Shares Issued For Conversion Of Accounts Payable CommonSharesIssuedForConversionOfAccountsPayable		usd
CY2023Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent		usd
CY2023Q4	us-gaap	Pension And Other Postretirement Defined Benefit Plans Current Liabilities PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities		usd
CY2023Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount		usd
CY2024Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised		shares
	BIXT	Share Based Compensation Arrangements By Share Based Payment Award Non Option Equity Instruments Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures And Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations		shares
	BIXT	Share Based Compensation Arrangements By Share Based Payment Award Non Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeituresInPeriodWeightedAverageExercisePrice
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted		shares
	BIXT	Share Based Compensation Arrangements By Share Based Payment Award Non Option Equity Instruments Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised		shares
	BIXT	Share Based Compensation Arrangements By Share Based Payment Award Non Option Equity Instruments Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures And Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations		shares
	BIXT	Share Based Compensation Arrangements By Share Based Payment Award Non Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeituresInPeriodWeightedAverageExercisePrice
CY2024Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	115031	usd
CY2024Q2	us-gaap	Assets Assets	128553	usd
CY2024Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	216526	usd
CY2024Q2	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	730000	usd
CY2023Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	1900000	usd
CY2024Q2	us-gaap	Liabilities Current LiabilitiesCurrent	1228509	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3249500	usd
CY2024Q2	us-gaap	Liabilities Liabilities	1228509	usd
CY2023Q4	us-gaap	Liabilities Liabilities	3249500	usd
CY2024Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2024Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000	shares
CY2024Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2024Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	177416428	shares
CY2024Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	177416428	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	145642333	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	145642333	shares
CY2024Q2	us-gaap	Common Stock Value CommonStockValue	177416	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	145642	usd
CY2024Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	16376479	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	12920984	usd
CY2024Q2	us-gaap	Minority Interest MinorityInterest	-694210	usd
CY2023Q4	us-gaap	Minority Interest MinorityInterest	-680886	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-16959641	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-15497602	usd
CY2024Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-1099956	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-3111862	usd
CY2024Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	128553	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	137638	usd
CY2023Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	149638	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	27000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	288642	usd
CY2024Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	441247	usd
CY2023Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	604932	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	608396	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	928070	usd
CY2024Q2	BIXT	General And Administrative Affiliate GeneralAndAdministrativeAffiliate	102447	usd
	BIXT	General And Administrative Affiliate GeneralAndAdministrativeAffiliate	572500	usd
CY2023Q2	us-gaap	Share Based Compensation ShareBasedCompensation	360	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	179101	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	1210	usd
CY2024Q2	BIXT	Stockbased Compensation Expense Affiliate StockbasedCompensationExpenseAffiliate	55000	usd
CY2023Q2	BIXT	Stockbased Compensation Expense Affiliate StockbasedCompensationExpenseAffiliate	4750	usd
	BIXT	Stockbased Compensation Expense Affiliate StockbasedCompensationExpenseAffiliate	186835	usd
	BIXT	Stockbased Compensation Expense Affiliate StockbasedCompensationExpenseAffiliate	17500	usd
CY2024Q2	us-gaap	Operating Expenses OperatingExpenses	609385	usd
CY2023Q2	us-gaap	Operating Expenses OperatingExpenses	1057680	usd
	us-gaap	Operating Expenses OperatingExpenses	1393176	usd
	us-gaap	Operating Expenses OperatingExpenses	1807922	usd
CY2024Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-609385	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-1057680	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-1393176	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-1807922	usd
CY2024Q2	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	19913	usd
CY2023Q2	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	39477	usd
	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	46647	usd
	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	106698	usd
CY2024Q2	BIXT	Interest Expense Affiliate InterestExpenseAffiliate	876	usd
	BIXT	Interest Expense Affiliate InterestExpenseAffiliate	1973	usd
CY2024Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1536	usd
CY2023Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2188	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	3567	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2702	usd
CY2024Q2	BIXT	Debt Discount Amortization And Issuance Of Warrants DebtDiscountAmortizationAndIssuanceOfWarrants	30000	usd
CY2023Q2	BIXT	Debt Discount Amortization And Issuance Of Warrants DebtDiscountAmortizationAndIssuanceOfWarrants	348637	usd
	BIXT	Debt Discount Amortization And Issuance Of Warrants DebtDiscountAmortizationAndIssuanceOfWarrants	30000	usd
	BIXT	Debt Discount Amortization And Issuance Of Warrants DebtDiscountAmortizationAndIssuanceOfWarrants	348637	usd
CY2024Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-52325	usd
CY2023Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-390302	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-82187	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-458037	usd
CY2024Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-661710	usd
CY2023Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1447982	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1475363	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2265959	usd
CY2024Q2	us-gaap	Profit Loss ProfitLoss	-661710	usd
CY2023Q2	us-gaap	Profit Loss ProfitLoss	-1447982	usd
	us-gaap	Profit Loss ProfitLoss	-1475363	usd
	us-gaap	Profit Loss ProfitLoss	-2265959	usd
CY2023Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-764	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-13324	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-33658	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-661710	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-1447218	usd
	us-gaap	Net Income Loss NetIncomeLoss	-1462039	usd
	us-gaap	Net Income Loss NetIncomeLoss	-2232301	usd
CY2024Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.00
CY2024Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.00
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.02
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.02
CY2024Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	176605978	shares
CY2024Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	176605978	shares
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	128804789	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	128804789	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	171264464	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	171264464	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	126224323	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	126224323	shares
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-3292546	usd
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	80000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	-30000	usd
CY2023Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-32894	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-785083	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-4060523	usd
CY2023Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	65000	usd
CY2023Q2	BIXT	Stock Issued During Period Value Issuance Stock Plan Affiliate StockIssuedDuringPeriodValueIssuanceStockPlanAffiliate	50200	usd
CY2023Q2	BIXT	Stock Issued During Period Value Issuance Issuance Stock Plan Other StockIssuedDuringPeriodValueIssuanceIssuanceStockPlanOther	1790	usd
CY2023Q2	BIXT	Stock Issued During Period Value Conversion Of Debt Affiliate StockIssuedDuringPeriodValueConversionOfDebtAffiliate	2164340	usd
CY2023Q2	BIXT	Stock Issued During Period Value Conversion Of Debt Other StockIssuedDuringPeriodValueConversionOfDebtOther	44050	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	172306	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	348637	usd
CY2023Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-764	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-1447218	usd
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-2662182	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-3111862	usd
CY2024Q1	BIXT	Stock Issued During Period Value Issuance Stock Plan Affiliate StockIssuedDuringPeriodValueIssuanceStockPlanAffiliate	131836	usd
CY2024Q1	BIXT	Stock Issued During Period Value Issuance Issuance Stock Plan Other StockIssuedDuringPeriodValueIssuanceIssuanceStockPlanOther	168448	usd
CY2024Q1	BIXT	Stock Issued During Period Value Conversion Of Debt Affiliate StockIssuedDuringPeriodValueConversionOfDebtAffiliate	485904	usd
CY2024Q1	BIXT	Stock Issued During Period Value Conversion Of Debt Other StockIssuedDuringPeriodValueConversionOfDebtOther	885404	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	1263562	usd
CY2024Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-13324	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-800329	usd
CY2024Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-990361	usd
CY2024Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-990361	usd
CY2024Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	63000	usd
CY2024Q2	BIXT	Stock Issued During Period Value Issuance Stock Plan Affiliate StockIssuedDuringPeriodValueIssuanceStockPlanAffiliate	30000	usd
CY2024Q2	BIXT	Stock Issued During Period Value Issuance Issuance Stock Plan Other StockIssuedDuringPeriodValueIssuanceIssuanceStockPlanOther	10695	usd
CY2024Q2	BIXT	Stock Issued During Period Value Conversion Of Debt StockIssuedDuringPeriodValueConversionOfDebt	286125	usd
CY2024Q2	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	162295	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-661710	usd
CY2024Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-1099956	usd
CY2024Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-1099956	usd
	us-gaap	Profit Loss ProfitLoss	-1475363	usd
	us-gaap	Profit Loss ProfitLoss	-2265959	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	30000	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	348637	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	3567	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2702	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	179101	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	1210	usd
	BIXT	Stockbased Compensation Expense Affiliate StockbasedCompensationExpenseAffiliate	186835	usd
	BIXT	Stockbased Compensation Expense Affiliate StockbasedCompensationExpenseAffiliate	17500	usd
	us-gaap	Paid In Kind Interest PaidInKindInterest	164357	usd
	us-gaap	Paid In Kind Interest PaidInKindInterest	7306	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	630286	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-106682	usd
	BIXT	Increase Decrease In Accounts Payable Affiliate IncreaseDecreaseInAccountsPayableAffiliate	151199	usd
	BIXT	Increase Decrease In Accounts Payable Affiliate IncreaseDecreaseInAccountsPayableAffiliate	1655113	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-130018	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-340173	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	7046	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	25047	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-7046	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-25047	usd
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	63000	usd
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	115000	usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	61500	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	124500	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	115000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-12564	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-250220	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	26086	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	295401	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	13522	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	45181	usd
	us-gaap	Interest Paid Net InterestPaidNet	52425	usd
	BIXT	Non Cash Issuance Of Warrants NonCashIssuanceOfWarrants	348637	usd
	BIXT	Debt Discount On Convertible Note DebtDiscountOnConvertibleNote	75000	usd
	BIXT	Common Shares Issued For Conversion Of Notes Payable And Accrued Interest CommonSharesIssuedForConversionOfNotesPayableAndAccruedInterest	1425857	usd
	BIXT	Common Shares Issued For Conversion Of Notes Payable And Accrued Interest CommonSharesIssuedForConversionOfNotesPayableAndAccruedInterest	172306	usd
	us-gaap	Stock Issued1 StockIssued1	1171529	usd
	BIXT	Common Shares Issued For Conversion Of Accounts Payable CommonSharesIssuedForConversionOfAccountsPayable	485904	usd
CY2024Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	177416428	shares
CY2024Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	177416428	shares
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_848_eus-gaap--UseOfEstimates_zoV7e5eiy67c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Use of Estimates</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of expenses during the reporting period. Significant estimates include the fair value of the Company’s stock, stock-based compensation, valuation of warrants, valuations in connection with convertible notes and the valuation allowance related to deferred tax assets. Actual results may differ from these estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	27000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	288642	usd
CY2024Q2	us-gaap	Cash Cash	13522	usd
CY2024Q2	BIXT	Working Capital WorkingCapital	-1214987	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-16959641	usd
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	63000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	61500	usd
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	115000	usd
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	usd
CY2023	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	usd
CY2024Q2	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P18Y
CY2024Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	130526	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	123480	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	15495	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	11928	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	115031	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	111552	usd
CY2024Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	41846	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	70895	usd
CY2024Q2	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	14058	usd
CY2024Q2	us-gaap	Pension And Other Postretirement Defined Benefit Plans Current Liabilities PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities	52434	usd
CY2024Q2	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	2682	usd
CY2023Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	1658	usd
CY2024Q2	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	730000	usd
CY2023Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	1900000	usd
CY2024Q2	us-gaap	Liabilities Current LiabilitiesCurrent	1228509	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3249500	usd
CY2024Q2	us-gaap	Accounts Payable Current And Noncurrent AccountsPayableCurrentAndNoncurrent	105252	usd
CY2023Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	1900000	usd
CY2023Q4	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	223759	usd
CY2023Q4	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	2123759	usd
CY2024Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2024Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000	shares
CY2023Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	123252235	shares
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	8515682	usd
CY2024Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	145642333	shares
CY2024Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	13066626	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	542030	shares
CY2022Q4	BIXT	Share Based Compensation Arrangement By Share Based Payment Award Non Options Equity Instruments Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice	0.42
CY2022	BIXT	Sharebased Compensation Arrangement By Sharebased Payment Award Non Option Equity Instruments Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm2	P4Y1M6D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	800000	shares
	BIXT	Share Based Compensation Arrangements By Share Based Payment Award Non Option Equity Instruments Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice	0.20
	BIXT	Sharebased Compensation Arrangement By Sharebased Payment Award Non Option Equity Instruments Outstanding Weighted Average Remaining Contractual Term Granted SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermGranted	P5Y
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	1342030	shares
CY2023Q2	BIXT	Share Based Compensation Arrangement By Share Based Payment Award Non Options Equity Instruments Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice	0.29
	BIXT	Sharebased Compensation Arrangement By Sharebased Payment Award Non Option Equity Instruments Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm2	P4Y4M24D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	1342030	shares
CY2023Q4	BIXT	Share Based Compensation Arrangement By Share Based Payment Award Non Options Equity Instruments Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice	0.29
CY2023	BIXT	Sharebased Compensation Arrangement By Sharebased Payment Award Non Option Equity Instruments Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm2	P3Y6M
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	1342030	shares
CY2024Q2	BIXT	Share Based Compensation Arrangement By Share Based Payment Award Non Options Equity Instruments Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice	0.29
	BIXT	Sharebased Compensation Arrangement By Sharebased Payment Award Non Option Equity Instruments Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm2	P3Y3M18D
CY2024Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding	0	usd
	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Lower Range Limit ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit	0.001
	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Upper Range Limit ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit	0.950
CY2024Q2	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	245000	shares
CY2024Q2	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1	0.78
	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P0Y2M4D
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	4320	usd
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P0Y2M4D
CY2024Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	4320	usd
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	6750	usd
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	0	usd
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	0	usd

Files In Submission

Name	View Source	Status
bixt-20240630_cal.xml	Edgar Link	unprocessable
0001493152-24-032356-index-headers.html	Edgar Link	pending
0001493152-24-032356-index.html	Edgar Link	pending
0001493152-24-032356.txt	Edgar Link	pending
0001493152-24-032356-xbrl.zip	Edgar Link	pending
bixt-20240630.xsd	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
bixt-20240630_def.xml	Edgar Link	unprocessable
bixt-20240630_lab.xml	Edgar Link	unprocessable
bixt-20240630_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BIXT
BIOXYTRAN, INC Stock $bixt

2024 Q3 Form 10-Q Financial Statement

#000149315224032356 Filed on August 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BIXT BIOXYTRAN, INC Stock $bixt

2024 Q3 Form 10-Q Financial Statement

#000149315224032356 Filed on August 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BIXT
BIOXYTRAN, INC Stock $bixt